Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Q-VD-OPH (Quinoline-Val-Asp-Difluorophenoxymethylketone) 是一种具有强效抗凋亡特性的泛半胱天冬酶抑制剂。它可抑制 HIV 感染,能透过血脑屏障。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 475 | 现货 | ||
5 mg | ¥ 1,420 | 现货 | ||
10 mg | ¥ 2,230 | 现货 | ||
25 mg | ¥ 4,270 | 现货 | ||
50 mg | ¥ 5,930 | 现货 | ||
100 mg | ¥ 8,160 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,760 | 现货 |
产品描述 | Q-VD-OPH (Quinoline-Val-Asp-Difluorophenoxymethylketone) is a pan-caspase inhibitor with potent antiapoptotic properties. |
靶点活性 | Caspase-1:25 nM-400 nM, Caspase-8:25 nM-400 nM, Caspase-9:25 nM-400 nM, Caspase-3:25 nM-400 nM |
体外活性 | Q-VD-OPh (5-100 μM) potently inhibits Actinomycin D-induced DNA laddering and subsequent apoptosis with minimal toxicity in WEHI 231 cells. Q-VD-OPh prevents caspase mediated cleavage of PARP and activation of the major initiator and effector caspases. [2] Q-VD-OPh protects cardiac myocytes from virus-induced apoptosis in vitro. [4] |
体内活性 | Q-VD-OPh inhibits caspase-1 activity, IL-18 protein expression, and neutrophil infiltration during ischemic ARF in mice. [3] In vivo, caspase inhibition by Q-VD-OPh provides protection from virus-induced myocardial injury, with a significant reduction in caspase-3 activity. [4] In TgCRND8 mice, Q-VD-OPh inhibits caspase-7 activation and limits the pathological changes associated with tau, including caspase cleavage. [5] |
激酶实验 | Enzyme assay is conducted in buffer containing 25 mM Tris, pH 8.0, 1 mM DTT, 1 mM spermine, 50 mM KCl, 0.01% Nonidet P-40, and 1 mM MgCl2. PARP reaction contains 0.1 μCi [3H]NAD+ (200?000 DPM), 1.5 μM NAD+, 150 nM biotinylated NAD+, 1 μg/mL activated calf thymus, and 1?5 nM PARP-1. Autoreactions utilizing SPA bead-based detection are carried out in 50 μL volumes in white 96-well plates. Compounds (e.g., MK-4827) are prepared in 11-point serial dilution in 96-well plate, 5 μL/well in 5% DMSO/Water (10× concentrated). Reactions are initiated by adding first 35 μL of PARP-1 enzyme in buffer and incubating for 5 min at room temperature and then 10 μL of NAD+ and DNA substrate mixture. After 3 h at room temperature, these reactions are terminated by the addition of 50 μL of streptavidin-SPA beads (2.5 mg/mL in 200 mM EDTA, pH 8). After 5 min, they are counted using a TopCount microplate scintillation counter. IC50 data is determined from inhibition curves at various substrate concentrations[1]. |
细胞实验 | Caspase inhibitors are added at the indicated concentrations 30 minutes prior to the addition of apoptotic stimuli. Viability and cell number are determined by trypan blue exclusion from three random fields of greater than 200 cells/field. All experiments are performed a minimum of three times.(Only for Reference) |
别名 | Quinoline-Val-Asp-Difluorophenoxymethylketone |
分子量 | 513.5 |
分子式 | C26H25F2N3O6 |
CAS No. | 1135695-98-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 100 mg/mL (194.75 mM)
DMSO: 50 mg/mL (97.37 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
Ethanol / DMSO | 1 mM | 1.9474 mL | 9.7371 mL | 19.4742 mL | 48.6855 mL |
5 mM | 0.3895 mL | 1.9474 mL | 3.8948 mL | 9.7371 mL | |
10 mM | 0.1947 mL | 0.9737 mL | 1.9474 mL | 4.8685 mL | |
20 mM | 0.0974 mL | 0.4869 mL | 0.9737 mL | 2.4343 mL | |
50 mM | 0.0389 mL | 0.1947 mL | 0.3895 mL | 0.9737 mL | |
Ethanol | 100 mM | 0.0195 mL | 0.0974 mL | 0.1947 mL | 0.4869 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Q-VD-OPH 1135695-98-5 Apoptosis Microbiology/Virology Proteases/Proteasome Caspase HIV Protease QVD-OPH QVDOPH inhibit Quinoline-Val-Asp-Difluorophenoxymethylketone Human immunodeficiency virus Inhibitor HIV Q VD OPH inhibitor